In this review, the authors summarized the preclinical and clinical evidence from over 700 patients in clinical trials of CD34+ cell therapy for ischemic events such as limb ischemia, myocardial ischemia, and cerebral ischemia. Here, CD34 is linked to myocardial ischemia.